Literature DB >> 22728873

The hemochromatosis proteins HFE, TfR2, and HJV form a membrane-associated protein complex for hepcidin regulation.

Flavia D'Alessio1, Matthias W Hentze, Martina U Muckenthaler.   

Abstract

BACKGROUND & AIMS: The hereditary hemochromatosis-associated membrane proteins HFE, TfR2, and HJV are required for adequate hepatic expression of the iron hormone hepcidin. While the genetic interactions are clear, it remains elusive how bone morphogenetic protein co-receptor HJV functions together with HFE and TfR2 to activate hepcidin transcription via the BMP-SMAD signaling pathway. Here, we investigate whether HFE, TfR2, and HJV physically interact on the surface of hepatocytes.
METHODS: We explore protein-protein interactions by glycerol gradient sedimentation assays and co-immunoprecipitation analyses in transfected HuH7 hepatoma-derived cells.
RESULTS: Our data demonstrate that HFE and TfR2 bind HJV in a non-competitive manner. Co-immunoprecipitation analyses provide direct experimental evidence that HFE, TfR2, and HJV form a multi-protein membrane complex. Our experiments show that like TfR2, HJV competes with TfR1 for binding to HFE, indicating that the expression of TfR2 and HJV may be critical for iron sensing. We identify residues 120-139 of the TfR2 extra-cellular domain as the critical amino acids required for the binding of both HFE and HJV. Interestingly, RGMA, a central nervous system homolog, can substitute for HJV in the complex and promote hepcidin transcription, implicating RGMA in the local control of hepcidin in the CNS.
CONCLUSIONS: Taken together, our findings provide a biochemical basis for hepcidin control by HFE, TfR2, and HJV.
Copyright © 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22728873     DOI: 10.1016/j.jhep.2012.06.015

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  71 in total

Review 1.  Crossing the Iron Gate: Why and How Transferrin Receptors Mediate Viral Entry.

Authors:  Marianne Wessling-Resnick
Journal:  Annu Rev Nutr       Date:  2018-05-31       Impact factor: 11.848

2.  The small molecule ferristatin II induces hepatic hepcidin expression in vivo and in vitro.

Authors:  Ahmed A Alkhateeb; Peter D Buckett; Andrew M Gardeck; Jonghan Kim; Shaina L Byrne; Paula G Fraenkel; Marianne Wessling-Resnick
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-04-23       Impact factor: 4.052

Review 3.  Liver iron sensing and body iron homeostasis.

Authors:  Chia-Yu Wang; Jodie L Babitt
Journal:  Blood       Date:  2018-11-06       Impact factor: 22.113

Review 4.  The liver: conductor of systemic iron balance.

Authors:  Delphine Meynard; Jodie L Babitt; Herbert Y Lin
Journal:  Blood       Date:  2013-11-07       Impact factor: 22.113

Review 5.  Iron and diabetes risk.

Authors:  Judith A Simcox; Donald A McClain
Journal:  Cell Metab       Date:  2013-03-05       Impact factor: 27.287

Review 6.  Iron and inflammation - the gut reaction.

Authors:  Smriti Verma; Bobby J Cherayil
Journal:  Metallomics       Date:  2017-02-22       Impact factor: 4.526

7.  How mutant HFE causes hereditary hemochromatosis.

Authors:  Martina U Muckenthaler
Journal:  Blood       Date:  2014-08-21       Impact factor: 22.113

8.  Endothelial Bone Morphogenetic Protein 2 (Bmp2) Knockout Exacerbates Hemochromatosis in Homeostatic Iron Regulator (Hfe) Knockout Mice but not Bmp6 Knockout Mice.

Authors:  Xia Xiao; Som Dev; Susanna Canali; Abraham Bayer; Yang Xu; Aneesh Agarwal; Chia-Yu Wang; Jodie L Babitt
Journal:  Hepatology       Date:  2020-05-22       Impact factor: 17.425

Review 9.  Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches.

Authors:  Paul J Schmidt; Mark D Fleming
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

Review 10.  The pathophysiology and pharmacology of hepcidin.

Authors:  Piotr Ruchala; Elizabeta Nemeth
Journal:  Trends Pharmacol Sci       Date:  2014-02-17       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.